IPP Bureau
OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
By IPP Bureau - July 04, 2022
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
By IPP Bureau - July 04, 2022
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
USFDA conducts inspection at Glenmark's Aurangabad manufacturing facility
By IPP Bureau - July 04, 2022
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
.jpg "Microsize launched as Independent pharma services company"){kind=logo}
Microsize launched as Independent pharma services company
By IPP Bureau - July 04, 2022
Meets the growing need for US-based API solubility and bioavailability enhancement services
Pfizer submits new drug application to the U.S. FDA for Paxlovid
By IPP Bureau - July 03, 2022
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer to achieve net-zero standard by 2040
By IPP Bureau - July 03, 2022
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Time to move from ‘Volume’ to ‘Value’ leadership to capture global market, says Mandaviya
By IPP Bureau - July 03, 2022
Govt committed to supporting pharma companies with industry-friendly policies
Maria Soler Nunez appointed Head, Group Operations of Lonza
By IPP Bureau - July 02, 2022
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
Lonza to invest 500 mn in commercial drug product fill & finish facility
By IPP Bureau - July 02, 2022
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
UK Parliament honours All India Institute of Ayurveda’s Director Dr Tanuja Nesari with Ayurveda Ratna Award
By IPP Bureau - July 02, 2022
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
By IPP Bureau - July 02, 2022
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
By IPP Bureau - July 02, 2022
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
NITI Aayog releases a compendium of Ayush-based practices
By IPP Bureau - July 02, 2022
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
Biosynth Carbosynth expands peptide offering with acquisition of Pepscan
By IPP Bureau - July 01, 2022
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
Jubilant HollisterStier announces CAD 100 mn for Montreal facility
By IPP Bureau - July 01, 2022
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
